PDS01ADC

Phase 2Small molecule

NNational Cancer Institute (NCI)

PDS01ADC is one of 65 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholangiocarcinomaActive, not recruiting

Prostate CancerActive, not recruiting

Cancer of ProstateRecruiting

Metastatic Colorectal Cancer (mcrc)Recruiting

Intrahepatic CholangiocarcinomaPhase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Cancer of ProstatePhase 2

Recruiting

Metastatic Colorectal Cancer (mcrc)Phase 2

Recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

PDS01ADC

NNational Cancer Institute (NCI)

Phase 2

2 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Preclinical

—10

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Advanced Cancers

NCT04708470

Phase 2Recruiting

Cancer of Prostate

NCT05361798

Phase 1/2Recruiting

Prostate Cancer

NCT04633252

Q4 2027

Phase 1Recruiting

Stereotactic Body Radiation Therapy (SBRT)

NCT04235777

Q4 2028

Phase 1/2Recruiting

Kaposi Sarcoma

NCT04303117

Phase 2Recruiting

Metastatic Colorectal Cancer (mcrc)

NCT05286814

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04633252·86 enrolled

Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT06096870·65 enrolled

Kaposi Sarcoma1 trial

PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

Recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04303117·80 enrolled

Advanced Cancers1 trial

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04708470·55 enrolled

Stereotactic Body Radiation Therapy (SBRT)1 trial

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04235777·100 enrolled

Metastatic Colorectal Cancer (mCRC)1 trial

Phase II Study Evaluating the Efficacy of PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05286814·70 enrolled

1 more indication

Cancer Of Prostate1 trial

A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05361798·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for PDS01ADC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PDS01ADC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PDS01ADC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

PDS01ADC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q4 2028

Trials by Indication[1]

Prostate Cancer2 trials

Kaposi Sarcoma1 trial

Advanced Cancers1 trial

Stereotactic Body Radiation Therapy (SBRT)1 trial

Metastatic Colorectal Cancer (mCRC)1 trial

Cancer Of Prostate1 trial

References

Drug Info

Quick Facts

Related News